83-5970-40 Tafolecimab (PCSK9) 100ug 592226
特徴
- GPRC5D/CD3 bispecific antibody is used to treat multiple myeloma.
- The bispecific antibody is commonly known as tafolecimab.
- It is constructed using the Duobody technology authorized by Genmab.
- The heavy chain of anti-CD3 antibody introduced F405L and R409K to construct the double antibody.
- S228P, F234A, and L235A mutations were simultaneously introduced into the IgG4 constant region.
- Applications:Suitable for use in ELISA and SDS-PAGE.
- Other applications not tested.
- Recommended Dilution:Optimal dilutions to be determined by the researcher.
- Storage and Stability:May be stored at 4℃ for short-term only.
- Aliquot to avoid repeated freezing and thawing.
- Store at -20℃.
- Aliquots are stable for 12 months after receipt.
- For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
- Size：100ug
- 抗体種類：Mab
- 宿主：human
- Grade：Highly Purified
- Purity：≥95%
- Form：Supplied as a liquid in PBS, pH 7.5.
- Specificity：Recognizes Tafolecimab (PCSK9).
- Isotype：IgG2,k
- Calc Applications Abbrev：E
- Immunogen：Recombinant protein corresponding to PCSK9 [Homo sapiens], expressed in CHO cells.
- この商品は法規制を確認しておりません。(法規制によって販売できない場合もございます)
- 製品の仕様は予告なく変更になる場合がございます。最新仕様はメーカーホームページをご確認ください。
- 【試薬に関するお問合せ】
- アズワン株式会社 試薬・プロセス材料グループ
- TEL：06-6447-8641
- FAX：06-6447-8642
- E-mail：[email protected]
